Stockholm, Sweden, April 4 , 2024
AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents to treat patients with heart failure, announced today that it has been selected as one of 11 finalists to present at the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. The summit will take place on May 14-15, 2024 at the Cleveland Clinic Abu Dhabi during the Abu Dhabi Global Healthcare Week. The aim is to bring together innovators, investors, and industry leaders to explore the latest advancements and trends shaping the future of healthcare. The finalists were selected from over 150 highly qualified applications submitted from around the globe and with a diverse range of companies and research institutions developing innovative therapeutic solutions. AnaCardio will be represented at the summit by CEO Patrik Strömberg.
“It is an honor for AnaCardio to be represented at this prestigious event. To be selected as a finalist amongst these highly innovative companies, which all have the potential to develop transformative treatments, is a great recognition of our efforts to bring our novel therapy to patients with heart failure.”, commented Patrik Strömberg.
More information about the summit and the selected finalists can be found here.
About AnaCardio
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is an oral ghrelin peptidomimetic small-molecule is being developed as a contractile agent in heart failure patients.
You can find more information about AnaCardio at www.anacardio.com.
For further information, please contact
Patrik Strömberg, CEO
Telephone: +46 704 156 159
E-mail: Patrik.stromberg@anacardio.com
